Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteVLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.
More Information Supplier PageVLX600 is a novel iron-chelating inhibitor of oxidative phosphorylation (OXPHOS), potentiates the effect of radiation in tumor spheroids in a synergistic manner. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. VLX600 induces autophagy and mitochondrial inhibition with antitumor activity.
More Information Supplier PageVLX600 is a novel iron-chelating inhibitor of oxidative phosphorylation (OXPHOS), potentiates the effect of radiation in tumor spheroids in a synergistic manner. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. VLX600 induces autophagy and mitochondrial inhibition with antitumor activity.
More Information Supplier PageVO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM.
More Information Supplier PageVO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM.
More Information Supplier PageVO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM.
More Information Supplier PageVO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM.
More Information Supplier PageVobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD.
More Information Supplier PageVobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD.
More Information Supplier PageVobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD.
More Information Supplier PageVodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.
More Information Supplier PageVodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.
More Information Supplier PageVofatamab (Anti-FGFR3 / CD333) is a monoclonal antibody targeting FGFR3. Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). MW: 145.5 KD.
More Information Supplier PageVofatamab (Anti-FGFR3 / CD333) is a monoclonal antibody targeting FGFR3. Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). MW: 145.5 KD.
More Information Supplier PageVofatamab (Anti-FGFR3 / CD333) is a monoclonal antibody targeting FGFR3. Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). MW: 145.5 KD.
More Information Supplier PageVoglibose (AO 128) is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.
More Information Supplier PageVoglibose (AO 128) is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.
More Information Supplier PageVolagidemab (Anti-GCGR) is an antagonistic monoclonal antibody (mAb) that targets glucagon receptor (GCGR). Volagidemab can be used in the research of type 1 diabetes (T1D). MW: 145.5 KD.
More Information Supplier PageVolagidemab (Anti-GCGR) is an antagonistic monoclonal antibody (mAb) that targets glucagon receptor (GCGR). Volagidemab can be used in the research of type 1 diabetes (T1D). MW: 145.5 KD.
More Information Supplier PageVolagidemab (Anti-GCGR) is an antagonistic monoclonal antibody (mAb) that targets glucagon receptor (GCGR). Volagidemab can be used in the research of type 1 diabetes (T1D). MW: 145.5 KD.
More Information Supplier PageVolasertib is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.
More Information Supplier PageVolasertib is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.
More Information Supplier PageVolasertib is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.
More Information Supplier PageVolasertib is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.
More Information Supplier PageVolasertib is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.
More Information Supplier PageVolinanserin (Volinanserin Hydrochloride Salt, MDL100907, M 100907, MDL-100,907) is a highly selective and potent 5-HT2 receptor antagonist with Ki of 0.36 nM. Volinanserin shows antipsychotic activity.
More Information Supplier Page
Volinanserin (Volinanserin Hydrochloride Salt, MDL100907, M 100907, MDL-100,907) is a highly selective and potent 5-HT2 receptor antagonist with Ki of 0.36 nM. Volinanserin shows antipsychotic activity.
More Information Supplier Page
Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD.
More Information Supplier PageVolociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD.
More Information Supplier PageVolociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD.
More Information Supplier PageVonafexor (EYP001, PLX007) is a novel non-bile acid, selective, second generation farnesoid X receptor (FXR) agonist.
More Information Supplier PageVonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD.
More Information Supplier PageVonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD.
More Information Supplier PageVonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD.
More Information Supplier PageVonoprazan Fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. Phase 3.
More Information Supplier PageVonoprazan Fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. Phase 3.
More Information Supplier PageVopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD.
More Information Supplier PageVopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD.
More Information Supplier PageVopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD.
More Information Supplier PageVorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
More Information Supplier PageVorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
More Information Supplier PageVorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
More Information Supplier PageVorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
More Information Supplier PageVorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
More Information Supplier PageVorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
More Information Supplier PageVorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
More Information Supplier PageVorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
More Information Supplier PageVorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
More Information Supplier PageVorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
More Information Supplier PageVorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
More Information Supplier Page
